May 1st 2024
FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.
What to Know about the Aprocitentan Approval for Resistant Hypertension, with Michael Weber, MD
March 25th 2024Michael Weber, MD, lead of the PRECISION trial, discusses the significance of the aprocitentan (Tryvio) approval and key points for providers who may have patients with uncontrolled hypertension.
Alirocumab Approved for Heterozygous Familial Hypercholesterolemia in Patients 8 Years and Older
March 11th 2024Nearly a decade after becoming the first PCSK9 inhibitor to receive approval from the FDA, alirocumab (Praluent) has now received approval for pediatric patients with HeFH based on data from a phase 3 trial.